[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337126-105":59,"doc-detail-337126-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","synthesis-and-biological-assessment-of-chalcone-and-pyrazoline-derivatives-as-novel-inhibitor-for-elf3-med23-interaction","Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction","","HER2 overexpression drives aggressive growth and recurrence across many solid tumors, making improved therapeutic options necessary as resistance to trastuzumab continues to emerge. This research targets the ELF3–MED23 protein–protein interaction as an alternative to HER2-directed antibody therapy. Twenty-six synthesized compounds were evaluated, including chalcones and pyrazoline acetyl/propionyl derivatives. Compound 10 showed strong potency by lowering ERBB2 promoter reporter activity via SEAP, disrupting ELF3–MED23 binding, reducing HER2 protein and mRNA, and suppressing downstream signaling. It induced apoptosis and inhibited proliferation in vitro and in vivo, including trastuzumab-refractory clones.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/synthesis-and-biological-assessment-of-chalcone-and-pyrazoline-derivatives-as-novel-inhibitor-for-elf3-med23-interaction/337126/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/synthesis-and-biological-assessment-of-chalcone-and-pyrazoline-derivatives-as-novel-inhibitor-for-elf3-med23-interaction/337126.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is HER2 a critical target in cancer therapy?","Question",{"text":112,"@type":113},"HER2 regulates key processes such as migration, proliferation, differentiation, and adhesion through HER family dimerization and downstream signaling. Its overexpression contributes to uncontrolled tumor progression and is associated with prognosis across multiple cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic strategy does the study propose instead of trastuzumab?",{"text":117,"@type":113},"The study proposes targeting the ELF3–MED23 protein–protein interaction as an alternative therapeutic approach. This aims to interfere with the interaction responsible for downstream HER2-related signaling.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the lead compound selected and what impact did it have?",{"text":121,"@type":113},"Candidate compound 10 was selected for potency in downregulating ERBB2 promoter reporter activity confirmed by SEAP activity. It disrupted ELF3 TAD binding to the MED23 region, reduced HER2 protein and mRNA levels, and inhibited downstream signals.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337126,1790212041,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","RESEARCH ARTICLE  \n*For correspondence:  \n[yna7315@cha.ac.kr](yna7315@cha.ac.kr) (YN);  \n[ykwon@ewha.ac.kr](ykwon@ewha.ac.kr) (YK)†These authors contributed equally to this work  \nCompeting interest: The authors declare that no competing interests exist.  \nFunding: See page 17  \nSent for Review  \n01 March 2024  \nPreprint posted  \n05 March 2024  \nReviewed preprint posted  \n04 June 2024  \nReviewed preprint revised  \n10 September 2024  \nVersion of Record published  \n05 December 2024  \nReviewing Editor: Alan Talevi, National University of La Plata, Argentina  \n Copyright Hwang, Jeon et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.  \nSynthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-  \nMED23 interaction  \nSoo-Yeon Hwang1†, Kyung-Hwa Jeon1†, Hwa-Jong Lee1, Inhye Moon1, Sehyun Jung1, Seul-Ah Kim1, Hyunji Jo1, Seojeong Park1, Misun Ahn1, Soo-Yeon Kwak2, Younghwa Na2*, Youngjoo Kwon1*  \n1College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea; 2College of Pharmacy, CHA University, Pocheon, Republic of Korea  \n\n| eLife assessment\u003Cbr>This valuable study characterized a new set of small molecules targeting the interaction between ELF3-MED23, with one of the reported compounds representing a promising novel therapeutic strategy, The evidence supporting the conclusions is convincing. This article will be of interest to medical and cell biologists working on cancer and, particularly, on HER2-overexpression cancers. |\n| --- |\n| Abstract HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success; however, readily emerging drug resistance emphasizes the pressing need for improved interventions in HER2-overexpressing cancers. To address this, we proposed targeting the protein-protein interaction (PPI) between ELF3 and MED23 as an alternative therapeutic approach to trastuzumab. In this study, we synthesized a total of 26 compounds consisting of 10 chalcones, 7 pyrazoline acetyl, and 9 pyrazoline propionyl derivatives, and evaluated their biological activity as potential ELF3-MED23 PPI inhibitors. Upon systematic analysis, candidate compound 10 was selected due to its potency in downregulating reporter gene activity of ERBB2 promoter confirmed by SEAP activity and its effect on HER2 protein and mRNA levels. Compound 10 effectively disrupted the binding interface between the ELF3 TAD domain and the 391–582 amino acid region of MED23, resulting in successful inhibition of the ELF3-MED23 PPI. This intervention led to a substantial reduction in HER2 levels and its downstream signals in the HER2-positive gastric cancer cell line. Subsequently, compound 10 induced significant apoptosis and anti-proliferative effects, demonstrating superior in vitro and in vivo anticancer activity overall. We found that the anticancer activity of compound 10 was not only restricted to trastuzumab-sensitive cases, but was also valid for trastuzumab-refractory clones. This suggests its potential as a viable therapeutic option for trastuzumab-resistant gastric cancers. In summary, compound 10 could be a novel alternative therapeutic strategy for HER2-overexpressing cancers, overcoming the limitations of trastuzumab. |\n\nHwang, Jeon et al. eLife 2024;13:RP97051. DOI: [https://doi.org/10.7554/eLife.97051](https://doi.org/10.7554/eLife.97051) 1 of 26  \n Research article Biochemistry and Chemical Biology | Medicine  \nIntroduction  \nHuman epidermal growth factor receptor 2 (HER2) belongs to the HER family, encompassing EGFR (HER1, erbB1), HER2 (HER2/neu, erbB2), HER3 (erbB3), and HER4 (erbB4) . Known as a protooncogene, HER2 play","cbCailDcvSNAeiUK","https://ap.wps.com/l/cbCailDcvSNAeiUK","pdf",11298266,26,"English","# Introduction\n## HER2 function and signaling pathways\n## HER2 overexpression across cancers\n## Prognostic implications and treatment relevance\n# Abstract\n## Rationale for targeting ELF3–MED23 PPI\n## Compound synthesis and biological evaluation\n## Effects of lead compound on HER2 and downstream signaling\n## Anticancer activity in trastuzumab-sensitive and -refractory contexts","[{\"question\":\"Why is HER2 a critical target in cancer therapy?\",\"answer\":\"HER2 regulates key processes such as migration, proliferation, differentiation, and adhesion through HER family dimerization and downstream signaling. Its overexpression contributes to uncontrolled tumor progression and is associated with prognosis across multiple cancer types.\"},{\"question\":\"What therapeutic strategy does the study propose instead of trastuzumab?\",\"answer\":\"The study proposes targeting the ELF3–MED23 protein–protein interaction as an alternative therapeutic approach. This aims to interfere with the interaction responsible for downstream HER2-related signaling.\"},{\"question\":\"How was the lead compound selected and what impact did it have?\",\"answer\":\"Candidate compound 10 was selected for potency in downregulating ERBB2 promoter reporter activity confirmed by SEAP activity. It disrupted ELF3 TAD binding to the MED23 region, reduced HER2 protein and mRNA levels, and inhibited downstream signals.\"}]","Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction | PDF",1790017795,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91779f627104e7d2f799b59ce09ba752.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/631ab99028a6c2a37358cc52475a3c28.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4fd7a0ed54f0d25f998cbc8fa9ffcea.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b423669491d9d47640201a8b05825238.webp",980,1268]